Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Insulin therapy Stories

2012-06-12 10:23:08

FARMINGTON, June 12, 2012 /PRNewswire-iReach/ -- Non-insulin dependent (Type 2) diabetes accounts for 90% of all diagnosed cases of diabetes. The leading non-insulin antidiabetic Actos will lose its patent exclusivity in August 2012, offering significant market opportunities for competing generics. Having accurate market data and analysis will be essential to companies seeking to compete in this space. With premium market research from the world's leading publishers, Global Information Inc....

2012-06-12 06:23:09

PHILADELPHIA, June 12, 2012 /PRNewswire/ -- One in four people with type 2 diabetes missed or did not dose their long-acting (basal) insulin correctly in the previous 30 days, according to a new global survey funded by Novo Nordisk. The GAPP2(TM) (Global Attitudes of Patients and Physicians) survey also found that more than a third experienced a self-treated low blood sugar event called hypoglycemia. The data was presented at the late-breaking poster session of the 72nd Scientific Sessions of...

2012-06-11 14:21:53

PHILADELPHIA, June 11, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced results from a Phase 2 study of prandial insulin formulations, which include the Company's recombinant human hyaluronidase (rHuPH20) enzyme, in patients with Type 1 diabetes. The study met its primary endpoint of A1C non-inferiority (A1C is a measure of average blood sugar over three months). Further, data from the study indicated that rHuPH20 reduced postprandial glycemic excursions, as...

2012-06-11 10:24:30

PHILADELPHIA, June 11, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced results from two Phase II studies of their investigational novel basal insulin analog, LY2605541. Results of the type 1 diabetes study showed that LY2605541 was associated with greater improvements of glycemic control (lowering blood sugar levels) than insulin glargine. In the type 2 diabetes study, the primary measure showed that LY2605541 and insulin glargine had similar...

2012-06-09 06:21:45

PARIS, France, June 9, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today data demonstrating Lyxumia®(*) (lixisenatide), a once-daily investigational GLP-1 agonist, in combination with basal insulin plus oral anti-diabetic agents (OADs), significantly reduced HbA1c - glycated hemoglobin - in people with type 2 diabetes who were either new to insulin therapy (as early as 12 weeks after initiation) or already treated with insulin (for...

2012-06-09 06:21:43

PHILADELPHIA, June 9, 2012 /PRNewswire/ -- Cebix Incorporated today announced that data from a Phase 1 study demonstrated that Ersatta(TM), the company's long-acting form of C-peptide, was well tolerated with no serious adverse events in patients with type 1 diabetes and exhibited a pharmacokinetic profile consistent with once-weekly dosing. The half-life of Ersatta was 6-7 days compared to one hour for the naturally occurring C-peptide. Ersatta is being developed as a disease-modifying...

2012-06-09 06:21:34

PHILADELPHIA, June 9, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented results from a Phase 4 study of Hylenex® recombinant (hyaluronidase human injection) in sensor augmented insulin analog pump (SAP) therapy in patients living with Type 1 diabetes. Interim data from this study indicate that pre-administration of Hylenex recombinant in the SAP provided a consistent ultrafast insulin action profile over the infusion set life that resulted in improved glucose...

2012-06-09 06:21:18

PHILADELPHIA, June 9, 2012 /PRNewswire/ -- Researchers at Metabolic Solutions Development Company, LLC (MSDC) have identified a mitochondrial protein complex through which anti-diabetic drugs exert their insulin sensitizing effects when used to treat patients diagnosed with type 2 diabetes. Findings from this research are being presented today at the 72nd Scientific Sessions of the American Diabetes Association. The newly identified mitochondrial protein complex is being referred to as the...

2012-06-09 02:20:22

PARIS, France, June 9, 2012 /PRNewswire/ -- Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus® (insulin glargine [rDNA origin] injection) versus sitagliptin. These data from the EASIE (Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naive Patients) study were presented at the American Diabetes Association 72nd Scientific Sessions....

2012-06-08 10:23:20

DANBURY, Conn., June 8, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) and Aegis Therapeutics, LLC (Aegis) today announced a partnership providing Biodel an exclusive worldwide license to Aegis' proprietary ProTek® and Intravail® technologies for the development and commercialization of pharmaceutical formulations of glucagon. ProTek® protein stabilization technology comprises the use of proprietary GRAS excipients that prevent aggregation of proteins and peptides thereby...


Latest Insulin therapy Reference Libraries

0_0d961f30bdfa64859d9b869b063ddcd2
2010-12-03 18:12:26

Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...

More Articles (1 articles) »